MARKETSnap
  • Gainers &
    Losers
  • Most Active &
    More
  • 52-Week
    High/Low
  • P/E
    Ratios
    • Large Caps
    • Absolute
    • Total Market PE
  • Stocks
    Performance
    • Large Caps
    • Absolute
  • Industries
    Performance
    • Industry
    • Sector
  • Dividends
  • 📅 Calendar
    • Earnings Calendar
    • Dividends Calendar
    • Economics Calendar
  • 🔧 Tools
    • 💰 Intrinsic Value Calculator
    • 📈 Compounding Calculator
    • 🤖 Stock Pick Screener
  • More
    • Charts
    • Investment Compounding Calculator
    • Commodities
    • Currencies
    • Economic Indicators
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
KOD stock logo

KOD

Kodiak Sciences Inc.

$83.79
-7.85
 (-8.56%)
Exchange:  NASDAQ
Market Cap:  5.243B
Shares Outstanding:  45.742M
Delayed data
Overview
Earnings
Financials
Valuation
Chart

About The Company

Sector:  HealthcareView sector performance
Industry:  BiotechnologyView industry performance
   
CEO:  Victor Perlroth
Full Time Employees:  141
Address: 
1200 Page Mill Road
Palo Alto
CA
94304
US
Website:  https://kodiak.com
Kodiak Sciences Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to discovering, advancing, and bringing to market treatments for various conditions affecting the retina. Their primary drug candidate, KSI-301, is an anti-vascular endothelial growth factor (anti-VEGF) antibody biopolymer. This compound is currently undergoing Phase IIb/III clinical trials, targeting illnesses such as wet age-related macular degeneration (AMD), diabetic macular edema, previously untreated macular edema resulting from retinal vein occlusion, and non-proliferative diabetic retinopathy. In its earlier, preclinical development pipeline, the company is also working on KSI-501, a bispecific conjugate designed for retinal conditions involving inflammation, and KSI-601, a triplet inhibitor aimed at addressing dry AMD. Established in 2009, this Palo Alto, California-based company operated under the name Oligasis, LLC before rebranding as Kodiak Sciences Inc. in September 2015.

Click to read more…

Revenue Segmentation

🔒 You are currently logged out

Login

It’s free

Industry Peers

TICKERCOMPANYMKT CAPP/EFWD P/EROIC
KOKOD logoKODKodiak Sciences Inc.5.2B——-115.2%
ERERAS logoERASErasca, Inc.5.1B——-37.5%
CGCGON logoCGONCG Oncology Inc.5.5B——-24.3%
PTPTCT logoPTCTPTC Therapeutics, Inc.5.0B—48.32.6%
TVTVTX logoTVTXTravere Therapeutics, Inc.4.9B——-6.2%
MIMIRM logoMIRMMirum Pharmaceuticals, Inc.4.9B——-13.1%

EPS

Historical EPS and analyst estimates in one chart. Log in for the full interactive view and links to detailed estimates.

Log in to continue

Log in for the full EPS chart and links to analyst estimates.

Login — it's free
View full analyst estimates

Earnings Call

No earnings call materials on file for this symbol yet.

Log in to continue

Log in to read the full transcript and AI-generated earnings summaries.

Login — it's free
Income Statement
Balance Sheet
Cash Flow Statement
Analyst Estimates

Income Statement

Year202320242025
Revenue000
Gross Profit-25,947-26,7060
EBITDA-234,531-149,501-203,647
Operating Income-277,321-186,849-234,388
Net Income-260,491-176,207-229,967

Log in to continue

Log in to see the income statement and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Balance Sheet

Year202320242025
Total Assets479,372335,578351,533
Total Liabilities213,591185,290194,150
Total Stockholders Equity265,781150,288157,383
Total Debt81,63270,34559,180
Cash and Cash Equivalents285,507168,074209,862

Log in to continue

Log in to see the balance sheet and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Cash Flow Statement

Year202320242025
Operating Cash Flow-154,183-117,319-136,008
Capital Expenditure-41,427-400-506
Free Cash Flow-195,610-117,719-136,514
Net Income-260,491-176,207-229,967
Net Change in Cash95,074-117,57341,788

Log in to continue

Log in to see the cash flow statement and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Analyst Estimates

Fiscal Year2030Research AccessResearch AccessResearch AccessResearch Access
Estimated Revenue (Low)819,745.427Research AccessResearch AccessResearch AccessResearch Access
Estimated Revenue (High)3,260,057.444Research AccessResearch AccessResearch AccessResearch Access
Estimated Revenue (Avg)1,597,247.500Research AccessResearch AccessResearch AccessResearch Access
Estimated Ebitda (Low)246,789.947Research AccessResearch AccessResearch AccessResearch Access
Estimated Ebitda (High)1,535,025.145Research AccessResearch AccessResearch AccessResearch Access
Estimated Ebitda (Avg)657,231.457Research AccessResearch AccessResearch AccessResearch Access
Estimated Net Income (Low)188,147.251Research AccessResearch AccessResearch AccessResearch Access
Estimated Net Income (High)1,205,853.057Research AccessResearch AccessResearch AccessResearch Access
Estimated Net Income (Avg)512,396.044Research AccessResearch AccessResearch AccessResearch Access
Estimated SGA Expense (Low)0Research AccessResearch AccessResearch AccessResearch Access
Estimated SGA Expense (High)0Research AccessResearch AccessResearch AccessResearch Access
Estimated SGA Expense (Avg)0Research AccessResearch AccessResearch AccessResearch Access
Estimated EPS (Avg)9.630Research AccessResearch AccessResearch AccessResearch Access
Estimated EPS (High)22.660Research AccessResearch AccessResearch AccessResearch Access
Estimated EPS (Low)3.540Research AccessResearch AccessResearch AccessResearch Access
Number of Analysts (Estimated Revenue)2Research AccessResearch AccessResearch AccessResearch Access
Number of Analysts (Estimated EPS)1Research AccessResearch AccessResearch AccessResearch Access

Log in to continue

Log in and subscribe to Full Access to see up to 5 years of analyst estimates.

Login — it's free

(* All numbers are in thousands)

Current Key Metrics

?Revenue
 (TTM)
: 
0  ?P/S
 (TTM)
: 
0
?Net Income
 (TTM)
: 
-260.491M  ?P/E
 (TTM)
: 
-23.84
?Enterprise Value
 (TTM)
: 
6.22B  ?EV/FCF
 (TTM)
: 
-38.9
?Dividend Yield
 (TTM)
: 
0%  ?Payout Ratio
 (TTM)
: 
0%
?ROE
 (TTM)
: 
-273.23%  ?ROIC
 (TTM)
: 
-115.23%
?Net Debt
 (TTM)
: 
-24.429M  ?Debt/Equity
 (TTM)
: 
1.57
?P/B
 (TTM)
: 
102.38  ?Current Ratio
 (TTM)
: 
2.49

Log in to continue

Log in to see all key valuation metrics and ratios for this symbol.

Login — it's free

Forward P/E Ratios

?

Forward P/E (Avg EPS estimate) — log in with Research Access for high/low estimates and the interactive table.

Forward P/E 1YResearch AccessResearch AccessResearch AccessResearch Access
N/AResearch AccessResearch AccessResearch AccessResearch Access

Log in to continue

Log in with Full Access for forward P/E high/low estimates and the full multi-year table.

Login — it's free

SWOT Analysis

🔒 You are currently logged out

Login

It's free

At what price to buy it? -
Intrinsic Value Calculator

Based on current fundamentals and analyst forecasts, MarketSnap estimates KOD intrinsic value between $109.54 – $109.54 per share. This depends on revenue growth, margins, and discount rate.

This is an automatic estimate. The most reliable way to know fair value for your own assumptions is to run the calculator below.


Calculate KOD Intrinsic Value

Common questions about KOD valuation

Is Kodiak Sciences Inc. (KOD) overvalued or undervalued right now?

MarketSnap estimates intrinsic value for Kodiak Sciences Inc. (KOD) using its proprietary valuation methodology, which incorporates discounted cash flow (DCF) analysis together with long-term earnings and fundamentals assumptions. By comparing intrinsic value to the current market price, long-term investors can see whether the stock screens as potentially overvalued, fairly valued, or undervalued today.

Is KOD a buy, hold, or sell for long-term investors?

MarketSnap does not give one-word “buy” or “sell” calls. Instead, it shows whether KOD trades at a premium or discount to its estimated intrinsic value, how sensitive that value is to growth and margin assumptions, and how the stock fits into a diversified, long-term portfolio so investors can make their own buy, hold, or sell decision.

What is KOD’s P/E ratio?

You can see KOD’s trailing P/E (TTM) and forward P/E estimates in the Current Key Metrics and Forward P/E Ratios sections above. The P/E ratio compares the current share price to earnings per share and helps investors gauge valuation relative to earnings.

How is intrinsic value calculated for KOD?

MarketSnap uses its own valuation framework—not a generic spreadsheet DCF alone. Future cash flows and earnings are projected, discounted, and combined with MarketSnap’s methodology so intrinsic value reflects fundamentals and long-term assumptions. You can run your own inputs and see the result using the Intrinsic Value Calculator above.

Is KOD a good long-term investment?

Whether KOD fits a long-term portfolio depends on your assumptions about growth, margins, and risk. MarketSnap provides the metrics, intrinsic value calculator, and SWOT context so you can form your own view rather than rely on a single buy/sell rating.

Research tools for Kodiak Sciences Inc.

  • Kodiak Sciences Inc. intrinsic value calculatorEstimate what the business is worth
  • Kodiak Sciences Inc. 5-year outlookWhat has to go right, and what could go wrong
KOD

1-day price chart preview. Log in for 1W through 5Y ranges and period tabs.

Daily snapshot

-8.56
MarketSnap

Trading Metrics:

Open: 90.48   Previous Close: 91.63
Day Low: 83.38   Day High: 90.62
Year Low: 12.64   Year High: 104
Price Avg 50: 51.15   Price Avg 200: 37.99
Volume: 921463   Average Volume: 1.384M

Log in to continue

Log in for multi-period charts (1W–5Y), period tabs, and the same layout as members.

Login — it's free
See in Nexus

Relevant news

Why Kodiak Sciences Skyrocketed Today
28-09-2026 22:38
Why Kodiak Sciences Skyrocketed Today
Kodiak Sciences Inc. (KOD) Discusses DAYBREAK Topline Data and Primary Endpoint Results Transcript
28-09-2026 13:43
Kodiak Sciences Inc. (KOD) Discusses DAYBREAK Topline Data and Primary Endpoint Results Transcript
Kodiak Sciences Says Eye Drug on Par with Regeneron's Medicine
28-09-2026 10:05
Kodiak Sciences Says Eye Drug on Par with Regeneron's Medicine
Why Regeneron Rival Kodiak Sciences Just Skyrocketed 90%-Plus
28-09-2026 09:03
Why Regeneron Rival Kodiak Sciences Just Skyrocketed 90%-Plus
Kodiak Sciences to Present Topline Results on September 28, 2026 from DAYBREAK Pivotal Phase 3 Study of Zenkuda and KSI-501 in Patients with Wet Age-Related Macular Degeneration
25-09-2026 18:01
Kodiak Sciences to Present Topline Results on September 28, 2026 from DAYBREAK Pivotal Phase 3 Study of Zenkuda and KSI-501 in Patients with Wet Age-Related Macular Degeneration
Kodiak CFO Sells $1 Million in Stock as Shares Surge 650%. What Investors Should Know
09-06-2026 19:44
Kodiak CFO Sells $1 Million in Stock as Shares Surge 650%. What Investors Should Know

DISCLAIMER: The stock market data provided on this website is for informational purposes only and is not intended for trading purposes. While we strive to provide accurate and timely information, we cannot guarantee that the information is accurate at the moment it is received or that it will continue to be accurate in the future. We are not responsible for any actions taken based on the information provided on this website. Always consult with a licensed financial professional before making any investment decisions.
Terms of Service

Copyright © 2025 MarketSnap. All rights reserved.

Contact Us

Privacy Policy

Cookie Policy

Terms of Service

Hover Image
MARKETSnap

Market

🇺🇸 United States

Language

    • Gainers & Losers
    • Most Active & More
    • 52-Week High/Low
    • Dividends
      • Large Caps
      • Absolute
      • Total Market PE
      • Large Caps
      • Absolute
      • Industry
      • Sector
  • Learn
  • 💰 Stock intrinsic value Calculator
  • 📈 Investment Compounding Calculator
  • 🤖 Stock Pick Screener
  • 📋 Watchlist & Portfolio
    • Earnings Calendar
    • Dividends Calendar
    • Economics Calendar
    • Commodities
    • Currencies
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
  • Investing Philosophy
  • Nexus
  • Login Login
  • Profile Profile
  • Watchlist & Portfolio Watchlist & Portfolio
  • My Valuations My Valuations
  • Settings Settings

Media

Watch Listen Read